Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Amit M Oza, Ursula A Matulonis, Susanne Malander, Stacie Hudgens, Jalid Sehouli, Josep M Del Campo, Dominique Berton-Rigaud, Susana Banerjee, Giovanni Scambia, Jonathan S Berek, Bente Lund, Anna V Tinker, Felix Hilpert, Isabel Palacio Vázquez, Véronique D'Hondt, Benedict Benigno, Diane Provencher, Joseph Buscema, Shefali Agarwal, Mansoor Raza Mirza

Research output: Contribution to journalJournal articleResearchpeer-review

37 Citations (Scopus)
Original languageEnglish
JournalThe Lancet. Oncology
Volume19
Issue number8
Pages (from-to)1117-1125
Number of pages9
ISSN1470-2045
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial'. Together they form a unique fingerprint.

Cite this